Literature DB >> 26445302

Trimetazidine Prevention of Contrast-Induced Nephropathy in Coronary Angiography.

Weijing Liu1, Qiang Ming, Jianying Shen, Yidong Wei, Weiming Li, Wei Chen, Yawei Xu.   

Abstract

BACKGROUND: Contrast-induced nephropathy (CIN) after coronary angiography is frequently observed in patients with chronic renal insufficiency and no effective measures have been developed for prevention of CIN. There is evidence showing that trimetazidine (TMZ) has renoprotective effect on CIN. This study was to evaluate the role of TMZ in the prevention of CIN in renal dysfunction patients undergoing coronary angiography.
METHODS: A total of 132 patients with renal dysfunction who underwent coronary angiography were enrolled in our study and divided into control group (n = 70) and TMZ group (n = 62). Standard hydration was administered in all the patients. In TMZ group, patients were administered TMZ orally for 48 hours before and 24 hours after coronary angiography. Serum creatinine (SCr) and cystatin (CysC) were detected before and after contrast media injection, and the incidence of CIN was evaluated according to the elevation of SCr. Adverse events were observed in 12 months.
RESULTS: In both groups, CysC and SCr increased significantly after coronary angiography and peaked at 24 and 48 hours, respectively. CysC and SCr were significantly lower in TMZ group than in control group after coronary angiography. The incidence of CIN and adverse events was reduced in TMZ group when compared with control group (P = 0.034 and P = 0.043, respectively).
CONCLUSIONS: TMZ in combination with standard hydration is more effective than isotonic saline alone in protecting renal function in patients with renal dysfunction who undergo coronary angiography and can reduce the adverse events within 12 months.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26445302     DOI: 10.1097/MAJ.0000000000000575

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  6 in total

1.  The effect of trimetazidine on preventing contrast-induced nephropathy after cardiac catheterization.

Authors:  Xingji Lian; Wenfei He; Huimin Zhan; Jiyan Chen; Ning Tan; Pengcheng He; Yuanhui Liu
Journal:  Int Urol Nephrol       Date:  2019-10-22       Impact factor: 2.370

2.  Potential Role of Allopurinol in Preventing Contrast-Induced Nephropathy in Patients Undergoing Percutaneous Coronary Intervention: A Randomized Placebo-Controlled Trial.

Authors:  Zahra Ghelich Khan; Azita Hajhossein Talasaz; Hamidreza Pourhosseini; Kianoush Hosseini; Mohammad Javad Alemzadeh Ansari; Arash Jalali
Journal:  Clin Drug Investig       Date:  2017-09       Impact factor: 2.859

Review 3.  Clinical effect of trimetazidine on prevention of contrast-induced nephropathy in patients with renal insufficiency: An updated systematic review and meta-analysis.

Authors:  Ziliang Ye; Haili Lu; Qiang Su; Wenqin Guo; Weiran Dai; Hongqing Li; Huafeng Yang; Lang Li
Journal:  Medicine (Baltimore)       Date:  2017-03       Impact factor: 1.889

4.  Effectiveness of contrast-associated acute kidney injury prevention methods; a systematic review and network meta-analysis.

Authors:  Khalid Ahmed; Terri McVeigh; Raminta Cerneviciute; Sara Mohamed; Mohammad Tubassam; Mohammad Karim; Stewart Walsh
Journal:  BMC Nephrol       Date:  2018-11-13       Impact factor: 2.388

5.  Pharmacological interventions for the prevention of contrast-induced acute kidney injury in high-risk adult patients undergoing coronary angiography: a systematic review and meta-analysis of randomised controlled trials.

Authors:  Alexander J Sharp; Nishith Patel; Barney C Reeves; Gianni D Angelini; Francesca Fiorentino
Journal:  Open Heart       Date:  2019-01-25

6.  Trimetazidine reduces contrast-induced nephropathy in patients with renal insufficiency undergoing coronary angiography and angioplasty: A systematic review and meta-analysis (PRISMA).

Authors:  Ashkan Heshmatzadeh Behzadi; Behzad Amoozgar; Shalini Jain; Noel Velasco; Umar Zahid; Hamidreza Abbasi; Lutfi Alasadi; Martin R Prince
Journal:  Medicine (Baltimore)       Date:  2021-03-12       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.